There have been major advances in our understanding of the cellular and molecular biology
of the human malignancies that are collectively referred to as ovarian cancer. At a recent …

… Prof Amit M Oza, MD Amit M Oza … Correspondence to: Prof Amit M Oza, Division of Medical
Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, …

Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …

Background Most women with newly diagnosed advanced ovarian cancer have a relapse
within 3 years after standard treatment with surgery and platinum-based chemotherapy. The …

Background Niraparib is an oral poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP)
1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought …

Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) …

Risk factors for Campylobacter infection in conventional broiler flocks in the time period up to
the first removal of birds to slaughter were investigated over a maximum of five consecutive …

Gynecological Cancer Intergroup (GCIG) and its member organizations: 1AGO-OVAR (Germany),
2ANZGOG (Australia–New Zealand), 4EORTC (Europe), 6GEICO (Spain), 9GINECO (…

Because of nonspecific symptoms at disease presentation and inadequate screening methods,
ovarian cancer is often advanced at the time of diagnosis results in a 10-year survival of …

Background Few biomarkers of ovarian cancer prognosis have been established, partly
because subtype-specific associations might be obscured in studies combining all …